Given this, the proposal of an upregulated AT1-CB1 receptor heteromer within activated hepatic stellate cells during liver fibrosis (150) presents a potential novel target in the treatment of liver fibrosis, and this has formed the basis of a recent patent for AT1-CB1 heteromer biased antibodies for the treatment of liver fibrosis (151). The gene discussed is AGTR1; the disease is Hepatic fibrosis.